Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders at Targeted Protein Degradation Summit

2023-10-30

WALTHAM, Mass.--(BUSINESS WIRE)-- Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present new preclinical data from its ATAC (ASGPR Targeting Chimera) degrader platform at the sixth annual Targeted Protein Degradation Summit being held in Boston on October 30 – November 2, 2023. ATACs are bifunctional molecules comprising one of Avilar’s novel ligands to the asialoglycoprotein receptor (ASGPR) conjugated to another ligand that binds to a disease-causing extracellular protein. ATACs work by shuttling pathogenic proteins from circulation into the endolysosome where the unwanted proteins are degraded. The presentation will showcase new ATAC mechanism of action studies that confirm Avilar’s ASGPR ligands retain key pH- and calcium-dependent binding properties similar to and consistent with the known behavior of well-characterized ASGPR ligands such as GalNAc. These properties enable normal ASGPR release and recycling after ATAC internalization within the early endosome, and further elucidate the ATAC mechanism to harness the natural ASGPR pathway for degradation of extracellular protein targets. New in vivo data will also be presented that robustly characterize the relationship between ATAC pharmacokinetics, binding properties of the ATAC ligands to ASGPR and target protein IgG, and ASGPR-mediated degradation. Details of the presentation are as follows: Title: Heterobifunctional Molecules That Induce Targeted Degradation of Extracellular Proteins Through the Cell-Surface Asialoglycoprotein Receptor Session: Expanding the Scope of TPD by Leveraging the Ability to Degrade Extracellularly Presenter: Jason Wiles, PhD, Vice President, Discovery and Preclinical Sciences Date and Time: Thursday, November 2, 11 a.m. ET The slides will be available on the Avilar website following the presentation. About Avilar Therapeutics Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary discovery platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. This platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging its ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar is based in Waltham, MA. For more information, please visit and follow us on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构